Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Клучни зборови
Апстракт
Опис
The treatment of acute pancreatitis with Intra-abdominal hypertension still no ideal method. At present, through fasting, fluid resuscitation, prevention of shock, to correct acid-base balance and electrolyte imbalance, acid suppression, inhibition of pancreatic secretion, rational use of antibiotics and other general of conservative treatment, such as the failure of conservative treatment may be open decompression surgery, but trauma, and high mortality. Therefore an urgent need to explore and establish effective treatment IAH and Abdominal compartment syndrome to improve SAP's cure rate and reduce mortality.
Neostigmine as an anti-cholinesterase drugs, through acetylcholine in cholinergic transmission and cholinesterase competitively binding site, inhibiting the hydrolysis of acetylcholine, enhance and strengthen the role of cholinergic excitatory parasympathetic activity , restore the patient's bowel movements, so that the body showed a muscarinic (M-like) effect. When gastrointestinal M receptor stimulant can enhance intestinal peristalsis, promote flatus, defecation.
The investigators observed neostigmine can effectively promote intestinal gas, fluid emptying, thereby reducing intra-abdominal pressure. Therefore, prospective studies are needed to clearly worth neostigmine in the treatment of acute pancreatitis with IAH efficacy and safety.
Датуми
| Последен пат проверено: | 08/31/2015 |
| Прво доставено: | 08/26/2015 |
| Поднесено е проценето запишување: | 09/03/2015 |
| Прво објавено: | 09/06/2015 |
| Последното ажурирање е доставено: | 09/03/2015 |
| Последно ажурирање објавено: | 09/06/2015 |
| Крај на датумот на започнување на студијата: | 08/31/2015 |
| Проценет датум на примарно завршување: | 11/30/2017 |
| Проценет датум на завршување на студијата: | 11/30/2017 |
Состојба или болест
Интервенција / третман
Drug: Neostigmine
Drug: The traditional treatment
Фаза
Групи за раце
| Рака | Интервенција / третман |
|---|---|
| Experimental: Neostigmine Intramuscular injection of neostigmine combined the traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines | Drug: Neostigmine Intramuscular injection of neostigmine |
| Other: The traditional treatment The traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines |
Критериуми за подобност
| Возраст подобни за студии | 18 Years До 18 Years |
| Полови квалификувани за студии | All |
| Прифаќа здрави волонтери | Да |
| Критериуми | Inclusion Criteria: 1. Meet the diagnostic criteria for diagnosis and treatment of acute pancreatitis in 2013 Chinese guide acute pancreatitis; 2. According to the diagnostic standard of intra-abdominal hypertension of World Society of the Abdominal Compartment Syndrome; 3. IAH I level or above; 4. IAH belong to the bloating, or at the same time, but by puncture drainage fluid after intra-abdominal hypertension and Abdominal compartment syndrome treatment is invalid; 5. Age 18-70 one full year of life; 6. Onset of pancreatitis within <=2 weeks; 7. And signed the informed consent of patients. Exclusion Criteria: 1. Mechanical intestinal obstruction patients; 2. Neostigmine taboo subjects; 3. Ming or mannitol allergic patients of neostigmine; 4. Refused to sign the informed consent. |
Исход
Мерки на примарниот исход
1. The change of intra-abdominal pressure From admission to seventh days [From admission to seventh days,Measured once every 6 hours]
Секундарни мерки на исходот
1. Intestinal motility and intestinal emptying function [From admission to seventh days]
2. Incidence and duration of abdominal compartment syndrome [From admission to seventh days]
3. Incidence and duration of organ failure [From admission to seventh days]
4. Mortality [From admission to seventh days]
5. Adverse events during treatment [From admission to seventh days]
6. the recurrence rate of Intra-abdominal hypertension [From admission to seventh days]
7. The Security of Neostigmine [From admission to seventh days]
